Learn all about Polylaminin, the substance that regenerates spinal cord injuries.

A polylaminin placed the Brazilian science at the heart of one of the most sensitive and promising debates in modern medicine: the real possibility of spinal cord regeneration after injuries considered irreversible. Developed by researchers at Federal University of Rio de JaneiroThe substance gained national attention after preliminary results indicated motor recovery in patients with complete spinal cord injury, a condition historically associated with very low rates of spontaneous improvement.

Between enthusiasm, scientific caution, and intense mobilization on social media, the topic brings together innovation, hope, and methodological rigor. In this article, you will understand... What is polylaminin, how does it act in the body, and what results have been observed?.

What is polylaminin and how does it act in the body?

A polylaminin it's a way stabilized and polymerized of the protein laminin, which exists naturally in the human body and is part of extracellular matrix of tissues — the “network” that holds cells together and guides their behavior. While laminin helps cells bind, survive, and migrate in the development of the nervous system, polylaminin is a lab-produced version that It organizes itself into a more stable and bioactive three-dimensional structure. for therapeutic use.

In the context of spinal cord injuries, the main problem is that... axonsThe "bridges" that allow neurons to send signals between the brain and the body are broken or damaged...interrupting motor and sensory communication. Typically, the body forms a scar at the site of the injury, creating a hostile chemical environment that prevents the natural regeneration of these tissues.

When polylaminin is applied directly to the injured area of ​​the spinal cord (usually during a surgical procedure), it acts as a physical and biochemical support at the site of the injury. This “biological bridge” fills the empty space and creates an organized substrate that can to guide axon growth, helping the surviving cells to reconnect.

In addition to functioning as a kind of scaffolding, polylaminate also offers important chemical signalsThese signals help stimulate the growth of nerve fibers and facilitate communication between neurons, something that the scar matrix alone cannot do. This dual role (physical support + biochemical signaling) is what makes the substance interesting for regeneration studies.

The therapeutic potential of polylaminin It goes beyond simply building a "support." In preclinical models, including animal experiments and initial reports in humans, researchers have observed that it can... to promote the reconstitution of neural connections, an essential step in recovering motor and sensory function that was lost after the injury.

It is important to highlight, however, that polylaminin It is still in the experimental phase of clinical research....and the mechanisms by which it acts in the human body are rigorously studied. Recent clinical trials, authorized by regulatory agencies such as... AnvisaThey seek to evaluate above all the safety and tolerability of the substancebefore confirming its effectiveness in large-scale treatments.

Tatiana Coelho de Sampaio, creator of polylaminin

The Brazilian scientist Tatiana Lobo Coelho de Sampaio She is a professor and researcher at Federal University of Rio de Janeiro (UFRJ) and has dedicated nearly three decades to the study of laminin and its applications in the regeneration of the nervous system. His academic career is marked by research in biochemistry and molecular biology, focusing on the structure and behavior of proteins. It was from this solid foundation in fundamental science that the discovery of polylaminin emerged, the result of years of investigation into how to organize laminin molecules more efficiently to stimulate neuronal growth.

Throughout her career, Tatiana has focused her studies on the so-called supramolecular structure of proteins, that is, on how molecules can associate to gain new biological properties. Polylaminin was born precisely from this approach: by reorganizing laminin into a stable and bioactive structure, her team identified an unprecedented potential to stimulate the regeneration of damaged neurons. The work did not emerge suddenly, but as a consequence of decades of basic research, often far from the spotlight.

The scientist recently gained national prominence by presenting the initial results of her research in interviews and public debates, including participation in the program. Live WheelAt the time, he reinforced the need for scientific caution, avoiding the use of the term "cure" and highlighting that the substance is still in the experimental phase. His public stance has been marked by a balance between enthusiasm for the results and responsibility in communication.

Tatiana She also positions herself as a defender of continued investment in science in Brazil. In her statements, she emphasizes that research on polylaminin was only possible thanks to persistence in basic science and work in public universities. She has already mentioned that... Loss of international patent applications The lack of resources highlighted structural challenges faced by Brazilian research, while simultaneously reigniting the debate about scientific sovereignty and national funding.

Beyond its scientific impact, her trajectory has gained symbolic significance. Becoming a female role model in a groundbreaking discovery reinforces the importance of women's presence in science and in leading cutting-edge research. Despite the sudden visibility, which she herself described as unexpected, Tatiana maintains her academic routine and continues to lead clinical studies that seek to validate, with methodological rigor, the therapeutic potential of polylaminin.

Bruno de Freitas case

The most recent results involving polylaminin they come from a pilot clinical study conducted by researchers from the Federal University of Rio de Janeiro. The research evaluated patients with complete spinal cord injury, a condition in which, according to medical literature, the chances of spontaneous motor recovery are quite small. Meta-analyses indicate that only about 9% a 10% These patients show significant functional improvement over time, even with intensive rehabilitation.

In the experimental study, eight patients They were monitored after the substance was applied directly to the injured area of ​​the spinal cord. According to data released by the team, six of the eight participants, the equivalent of 75% of the sampleThey exhibited some degree of recovery of motor functionAlthough the number is still limited, the difference compared to natural recovery rates has drawn attention, indicating a possible breakthrough in the field of... regenerative medicine.

The researchers emphasize that this is an initial phase of the investigation. Pilot studies focus primarily on evaluating Safety, observe preliminary signs of efficacy and to structure protocols for broader stages. Polylaminin is advancing towards the phases 1 and 2 of clinical trials, which seek to formally validate their safety, standardize application criteria, and expand the number of volunteers evaluated.

Among the cases that gained the most attention is that of Bruno de Freitas, patient who suffered a complete cervical lesion in 2018 and participated in the experimental study. After treatment with polylaminin and a prolonged period of intensive physiotherapyBruno reported having recovered his functional independenceIn interviews, he stated that the The substance was crucial for the resumption of the movements., but he stressed that the result required about two years of continuous rehabilitation.

The case gained enormous visibility in social media, especially after the release of videos in which Bruno appears training at the gym and doing weight trainingThe images impressed because strength, balance and autonomy demonstrated, transforming its trajectory into a symbol of the therapeutic potential of research. The digital impact broadened the public debate and placed polylaminin at the center of discussions about scientific innovation in Brazil.

Despite the encouraging results, the team led by Tatiana Lobo Coelho de Sampaio emphasizes that it is not yet possible to say... definitive cure for spinal cord injuries. The data indicate a potential for functional recovery above expectationsbut scientific confirmation depends on larger, controlled, peer-reviewed studiesThe progress is considered promising, but it is still undergoing a rigorous process. clinical validation.

Next Steps

Studies with polylaminin They follow a path foreseen in Clinical trialsThis is an essential step to scientifically confirm the safety and efficacy of the substance. After promising initial results in pilot studies, scientific teams are now focused on expanding controlled research, aligning rigorous protocols, and evaluating potential adverse effects before moving on to broader phases of human testing. These steps are fundamental for any drug to be considered safe for more widespread use.

At the same time, the discussion about experimental design and methodological rigor is at the heart of the scientific debate. Experts emphasize the importance of well-structured studies, including control groups and clear criteria, to ensure that the observed benefits can be directly attributed to polylaminin and not to external factors or the natural evolution of the clinical condition.

Start of clinical trial phases

The first major milestone of this stage occurred when the Anvisa authorized the start of Phase 1 clinical trials with polylaminin in humansThis initial phase involves a small number of volunteers with acute spinal cord injury and focuses primarily on evaluating the treatment safety in humans, observing how the body reacts to the substance and whether there are significant adverse effects to be monitored.

In this phase 1, studies are being conducted with patients who have suffered recent complete spinal cord injuriesTypically, the substance is administered shortly after the trauma, in a controlled manner. The goal is not yet to prove the effectiveness of polylaminin in restoring movement, but to ensure that it does not cause harm and that it can be safely studied in the next stages.

After this stage is completed, if the safety data is positive, the protocol provides for progression to... phases 2 and 3 of clinical trialsThese studies involve more participants and allow for the comparison of different dosages and controlled study groups to validate therapeutic efficacy in a broader setting. This progress typically takes years and requires consistent results and review by regulatory agencies before any drug can be approved.

Distribution via SUS

The possibility that the polylaminin be made available by Unified Health System (SUS) It is already being publicly debated and mentioned by the research team itself. The intention is that, if the substance obtains regulatory registration with Anvisa (Brazilian Health Regulatory Agency) after the completion and approval of the clinical trial phases....so that it can be offered free of charge in the public system, expanding access to patients with spinal cord injuries who would not have another innovative therapeutic alternative.

This discussion also drives political and legislative initiatives in different states to ensure that, once approved, the incorporation of polylaminin into the SUS (Brazilian Public Health System) is effective and does not depend solely on... judicial use or isolated casesThis type of project aims to prevent inequalities in access and facilitate the adoption of highly complex treatments by the public health system.

The scenario of a future distribution by SUS This represents an important milestone in the history of Brazilian public medicine. If confirmed, it could make a potentially transformative treatment accessible to a much larger segment of the population living with the consequences of spinal cord injuries.

The issue of judicialization and compassionate use.

The use of polylaminin Use of the substance outside of formal clinical trials has grown in Brazil through petitions to the courts to release the substance based on what is called... compassionate use, which is a mechanism regulated by Anvisa to allow access to experimental treatments in severe cases when no therapeutic alternatives are available. This instrument has been applied in judicial decisions authorizing patients with acute spinal cord injury receiving the substance even before the completion of the full testing phases, as occurred in one case in Goiâniawhere a quadriplegic patient underwent the procedure in January through this exceptional authorization.

Despite enabling rapid access in critical situations, researchers, including Tatiana Lobo Coelho de Sampaio, they warn that the Legal action can hinder the scientific conduct of research with polylaminin.This is because patients treated under court orders or compassionate use releases are often not subject to the same rigorous monitoring protocol as official clinical trials, creating gaps in the monitoring of adverse effects or actual improvements. Without this systematic monitoring, valuable information that could guide later phases of testing and safety analysis may be lost.

Another important aspect is that, to date, there are dozens of approved court orders for the use of the substance outside of controlled contexts, and in many cases, the applications occur without a formal requirement for data to be returned to the research team. This creates a scenario in which important clinical information—such as treatment response, side effects, and functional evolution—may not be reported in a standardized manner or shared with the researchers responsible for the study. Scientists and experts emphasize that, although compassionate use addresses an individual need in severe cases, it This does not replace controlled and regulated studies., which are essential for validating safety and efficacy before any broader approval.

What is your opinion on the development of Polylaminin? Tell us in the comments below!

See also:

Source: Frontiers.

reviewed by Luis Antonio Costa in 26 / 02 / 2026